Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: The ARCOS study

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 2, 2006, Pages 368-376

  Zanella, Maria Teresa ^a,d   Uehara, Marcelo Hiroshi ^a   Ribeiro, Artur Beltrame ^a   Bertolami, Marcelo ^b   Falsetti, Ana Claudia ^c   Yunes, Mirela A ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Service of Cardiology   (United States)

^c Roche Laboratories   (Brazil)

^d NONE   (Brazil)

Author keywords

Cardiovascular risk; Central obesity; Framingham risk score; Orlistat; Weight reduction

Indexed keywords

ANTIOBESITY AGENT; LACTONE; TETRAHYDROLIPSTATIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; DIET THERAPY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; WAIST HIP RATIO; WEIGHT REDUCTION;

ADULT; AGED; ANTI-OBESITY AGENTS; BLOOD PRESSURE; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LACTONES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; WAIST-HIP RATIO; WEIGHT LOSS;

EID: 33744494307     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302006000200023     Document Type: Article

References (32)

1. Cohn JN. Arteries, myocardium, blood pressure and cardiovascular risk: towards a revised definition of hypertension. J Hypertens 1998;1612 (pt2):2117-24.
2. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003;108:1541-5.
3. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004;43:1817-22.
4. Lean ME, Han TS, Morrison CE. Waist circumference as a measure indicating need for weight management. BMJ 1995;311:1150-62.
5. Han TS, van Leer EM, Seidell JC, Lean ME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 1995;311:1401-5.
6. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA1999;282:1523-9.
7. Pfohl M, Luft D, Blomberg I, Schmulling RM. Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. Int J Obes 1994;18:391-5.
8. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975-90.
9. Eriksson KF, Lindgärde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia 1998;41:1010-6.
10. Kramer FM, Jeffery RW, Forster JL, Snell MK. Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women. Int J Obes 1989;13:123-36.
11. Wadden TA. Treatment of obesity by moderate and severe calorie restriction: results of clinical research trials. Arch Intern Med 1993;119:688-93.
12. Grodstein F, Levine R, Troy L, Spencer T, Colditz GA, Stampfer MJ. Three-year follow-up of participants in a commercial weight loss program. Can you keep it off? Arch Intern Med 1996;156:1302-6.
13. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002;4:415-23.
14. Lindgärde F; The Orlistat Swedish Multimorbidity Study Group. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000;248:245-54.
15. Ribeiro Filho FF, Faria NA, Azjen S, Zanella MT, Ferreira SR. Methods of estimation of visceral fat: advantages of ultrasonography. Obes Res 2003;11:1488-94.
16. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;12:1837-47.
17. Ditschuneit HH, Flechtner-Mors M, Johnson TD, Adler G. Metabolic and weight-loss effects of a long-term dietary intervention in obese patients. Am J Clin Nutrition 1999;6969:198-204.
18. Wing RR, Jeffery RW. Effect of modest weight loss on changes in cardiovascular risk factors: are there differences between men and women or between weight loss and maintenance? Int J Obes Relat Metab Disord 1995;19:67-73.
19. Flechtner-Mors M, Ditschuneit HH, Johnson TD, Suchard MA, Adler G. Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obesity Res 2000;8:399-402.
20. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes 1997; 21(suppl. 1):S5-9.
21. Thomas PR. Weighing the options. Criteria for evaluating weight management programs. Washington (DC): National Academy Press; 1995.
22. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-72.
23. .Van Gaal LF, Broom JI, Enzi G, Toplak H; Orlistat Dose Ranging Study Group. Efficacy and tolerability of orlistat in the treatment of obesity: a 6 month dose ranging study. Eur J Clin Pharmacol 1998;54:125-32.
24. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G; the European Orlistat Obesity Study. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000;8:49-61.
25. Larsson B. Obesity and body fat distribution as predictors of coronary heart disease. In: Marmot M, Elliott P, eds. Coronary Heart Disease Epidemiology. From Aetiology to Public Health. Oxford:Oxford University Press; 1992. p.233-41.
26. Faria AN, Ribeiro Filho FF, Kohlmann NE, Gouvea Ferreira SR, Zanella MT. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. Diabetes Obes Metab 2005;7:246-53.
27. McCarron DA, Reusser ME. Reducing cardiovascular disease risk with diet. Obes Res 2001;9:335S-40S.
28. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;2:233-40.
29. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6.
30. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
31. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002:346:393-403.
32. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.